Company invites individual and institutional investors to attend interactive real-time virtual roadshow
NEW YORK, May 5, 2015 /CNW/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on May 7, 2015.
DATE: Thursday, May 7, 2015
TIME: 11:30 am ET/8:30 am PT
LINK: http://VirtualInvestorConferences.com > click the red "register/ watch presentations" button
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells. To learn more about ImmunoCellular, please visit www.imuc.com.
VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE ImmunoCellular Therapeutics, Ltd.
For further information: ImmunoCellular Therapeutics, Ltd., Jane Green, 415.348.0010 direct, 415.652.4819 mobile, firstname.lastname@example.org; or VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, email@example.com, http://www.imuc.com